BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Perrigo Company (PRGO) Announces Pricing of $2,300,000,000 Senior Notes


11/6/2013 10:02:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALLEGAN, Mich.
and DUBLIN, Nov. 5, 2013 /PRNewswire/ -- Perrigo Company Limited, a limited company incorporated under the laws of Ireland ("Issuer"), announced that it has priced an offering of $2,300,000,000 aggregate principal amount of senior notes, consisting of $500,000,000 aggregate principal amount of 1.30% Senior Notes due 2016, $600,000,000 aggregate principal amount of 2.30% Senior Notes due 2018, $800,000,000 aggregate principal amount of 4.00% Senior Notes due 2023 and $400,000,000 aggregate principal amount of 5.30% Senior Notes due 2043.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

The Issuer intends to use the net proceeds from the offering, together with proceeds from its credit facilities and certain cash, to fund the cash purchase price of the previously announced acquisition (the "Acquisition") by Perrigo Company, a Michigan Corporation ("Perrigo") (NYSE/TASE: PRGO), of Elan Corporation, plc, a public limited company incorporated under the laws of Ireland ("Elan"), to refinance certain outstanding indebtedness of Perrigo and to pay related fees and expenses.

The offering of the notes is expected to close on November 8, 2013, which is prior to the expected date of the consummation of the Acquisition. Pending consummation of the Acquisition, the net proceeds from the offering (after payment of certain hedging and other transaction related expenses) will be deposited into an escrow account. If the Acquisition is not consummated for any reason on or prior to April 29, 2014, which may be extended in certain circumstances to July 29, 2014, the proceeds from the offering will be used to redeem the notes at a redemption price of 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest to, but not including, the redemption date.

The notes will be guaranteed on a senior unsecured basis by (i) upon the closing of the offering, certain of the Issuer's subsidiaries that were formed for the purpose of facilitating the Acquisition, (ii) substantially concurrently with the consummation of the Acquisition and the release of the escrow property from the escrow account, Perrigo and certain subsidiaries of Perrigo that will guarantee the Issuer's new term loan credit facility and revolving credit facility (together, the "Permanent Credit Facilities") and (iii) within 60 days after the consummation of the Acquisition, Elan and certain of Elan's subsidiaries that will guarantee the Permanent Credit Facilities.

The notes are being offered and sold to qualified institutional buyers in the United States pursuant to Rule 144A and outside the United States pursuant to Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The notes have not been registered under the Securities Act, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and the rules promulgated thereunder.

The Issuer has agreed to file with the SEC a registration statement under the Securities Act with respect to a registered offer to exchange the notes and related guarantees for registered Notes and related guarantees of such series, within 365 days after the issue date, subject to certain conditions.

No Offer or Solicitation

This announcement is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Cautionary Statement regarding Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Issuer's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Issuer or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Issuer has based these forward-looking statements on its current expectations, assumptions, estimated and projections. While the Issuer believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Issuer's control. These and other important factors, including those discussed under "Risk Factors" in Perrigo's Form 10-K for the year ended June 29, 2013, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially form those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date here, and unless otherwise required by applicable securities laws, the Issuer disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Irish Takeover Rules

The Perrigo Company directors accept responsibility for the information contained in this communication. To the best of the knowledge and belief of the Perrigo Company directors (who have taken all reasonable care to ensure that such is the case), the information in this communication is in accordance with the facts and does not omit anything likely to affect the import of such information.

Persons interested in 1% or more of any relevant securities in Perrigo or Elan may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2007 (as amended).

SOURCE Perrigo



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES